Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Dec 30;22(1):322–323. doi: 10.1111/ajt.16775

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

(A) Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies before and after vaccination in patients tested with different assays. Results are expressed as means ± SEM. ****p < .0001. (B) Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies before and after vaccination in patients tested with the Wantai enzyme-linked immunosorbent assay test. Results are expressed as means ± SEM. ****p < .0001. (C) Anti-SARS-CoV-2 antibodies titers before and after vaccination in patients who were tested with the Wantai test and who had no detectable antibodies titers before the third dose. A positive test using the Wantai assay was defined by a signal-to-cut-off ratio (S/CO) >1.1. ****p < .0001. (D) Anti-SARS-CoV-2 antibody titers before and after vaccination in patients who were tested with the Wantai test and who had detectable antibodies titers before the third dose. Results are expressed as means ± SD. A positive test using the Wantai assay was defined by a S/CO >1.1. ***p = .004. **p = .017 [Color figure can be viewed at wileyonlinelibrary.com]